Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 3/20 | 0.38 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.36 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3456757 | 0.83 | MCHR1 (0.48) | HRH3MCHR1MAOBKIF11MEN1 | |
| SCHEMBL11939552 | 0.80 | MAOB (0.44) | MCHR1MAOBMEN1LMNAKMT2A | |
| SCHEMBL2650572 | 0.78 | SLC6A4 (0.46) | MCHR1LMNA | |
| SCHEMBL11464709 | 0.76 | MEN1 (0.50) | HRH3MCHR1MEN1LMNAKMT2A | |
| SCHEMBL14021244 | 0.76 | HRH4 (0.50) | HRH3MAOBKIF11RORC | |
| SCHEMBL8079472 | 0.76 | MAOB (0.49) | MAOBMEN1 | |
| SCHEMBL3455748 | 0.75 | HRH4 (0.50) | HRH3MCHR1MAOBKIF11LMNA | |
| SCHEMBL22733029 | 0.74 | HRH3 (0.44) | HRH3MAOBKIF11PLA2G7 | |
| SCHEMBL6357114 | 0.74 | MAOB (0.49) | HRH3MAOBKIF11MEN1KMT2A | |
| SCHEMBL11939551 | 0.73 | HRH3 (0.45) | HRH3MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015087239-A1 | PROCESSES FOR THE PREPARATION OF DARAPLADIB AND ITS INTERMEDIATES | RANBAXY LABORATORIES LIMITED (IN) | 2015-06-18 | — | — | WO | claimed |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY | 2015-07-02 | — | — | US | disclosed |
| US-9029383-B2 | Methods of treatment of skin ulcers | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2152865-B1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | UNIV JEFFERSON (US) | 2015-04-15 | — | — | EP | disclosed |
| US-20130150379-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2013-06-13 | — | — | US | disclosed |
| US-20100239565-A1 | METHODS OF TREATMENT OF SKIN ULCERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-09-23 | — | — | US | disclosed |
| EP-1337517-A1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002030911-A1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | PLA2G12A, PLA2G3, PLA2G4A | HRH3 719/4885MCHR1 4600/4885MAOB 758/4885 |
| US-20130150379-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, PLA2G1B, PLA2G2A | HRH3 1428/4885MCHR1 3499/4885MAOB 180/4885 |
| US-20100239565-A1 | METHODS OF TREATMENT OF SKIN ULCERS | PLA2G12A, PLA2G3, PLA2G4A | HRH3 719/4885MCHR1 4600/4885MAOB 758/4885 |
| US-20150183748-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, LPAR1, PLA2G1B | HRH3 1198/4885MCHR1 1774/4885MAOB 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.